US drug distribution revenue for the Big Three wholesalers is projected to reach $933bn in 2026, as growth slows and the companies push into physician services.
The projection comes from the Drug Channels Institute (DCI), whose annual economic report on pharmaceutical wholesalers and specialty distributors is due on 12 October. The Big Three are McKesson, Cencora and Cardinal Health.
The numbers at a glance
- Projected 2026 revenue: $933bn for the Big Three’s drug distribution businesses
- Growth: Slowing from double digits to mid-single digits
- Investment in physician services: More than $20bn put into physician management services organisations (MSOs)
Why wholesalers are buying into care
The more than $20bn invested in physician MSOs shows wholesalers moving closer to where specialty drugs are prescribed and given, especially in oncology and other specialist practices. Owning or backing these practices gives distributors a steadier, higher-margin business alongside the low-margin job of moving medicines.
Why it matters
- Slower growth, new bets. As drug revenue growth cools, wholesalers are looking for higher-margin businesses.
- Scale is concentrated. Three companies handle the bulk of US drug distribution, so their strategy affects almost every hospital and pharmacy.
- More control of the channel. Owning physician services and infusion gives wholesalers more influence over which products are used.
What it means for hospitals and pharmacies
Hospitals, clinics and pharmacies buy from a small number of very large wholesalers. As those wholesalers own more physician practices and care services, buyers should watch for changes in pricing, preferred product lists and service terms. For manufacturers, wholesaler strategy increasingly shapes how specialty drugs reach patients.
The bottom line
The Big Three are growing more slowly but becoming more powerful, using their scale to move deeper into patient care. That shift will shape drug access and pricing for years.
Frequently Asked Questions
How big is US drug wholesaling? DCI projects $933bn in 2026 drug distribution revenue for the Big Three wholesalers.
Who are the Big Three? McKesson, Cencora and Cardinal Health.
Why are wholesalers investing in physician practices? To move closer to where specialty drugs are prescribed and given, and to find growth as distribution slows.
When is the full report published? The Drug Channels Institute’s 2026-27 report on wholesalers and specialty distributors is due on 12 October 2026.
Sources
| Source | Used for |
|---|---|
| Drug Channels | Revenue projection, growth outlook, MSO investment, report release date |
Additional Resources
| Resource | What you’ll find |
|---|---|
| Healthcare Distribution Alliance (HDA) | US pharmaceutical distribution industry data |
| McKesson, Cencora and Cardinal Health investor relations | Company results and strategy |
| Association for Accessible Medicines (AAM) | Generic and biosimilar market data |
| IQVIA Institute for Human Data Science | US medicine spending reports |
Data note: Figures are projections from the Drug Channels Institute, not reported company results. The full report is due on 12 October.